Rocket Pharmaceuticals, Inc. RCKT
2.38 USD -0.23 (-9.00%)
Nov 5, 2026, 10:31 AM EST
2.36 Day range 2.58
2.17 52-week range 5.45
- YTD
- -32.34%
- 1 year
- -28.46%
News
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.
benzinga.com Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4 Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.
benzinga.com Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4 Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.- benzinga.com Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and…
- benzinga.com Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
benzinga.com This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.
benzinga.com This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.- benzinga.com Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.
benzinga.com Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.
benzinga.com Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited…
benzinga.com Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15 Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.- benzinga.com Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over…
benzinga.com Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.
benzinga.com Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observedRocket is actively engaging with the FDA to align on the path to pivotal trial…
benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I…- benzinga.com Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of…
benzinga.com Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at benzinga.com/analyst-stock-ratings- benzinga.com B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9 B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $8 to $9.
benzinga.com Why Is Rocket Pharma Stock Soaring Friday? Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash runway and support growth plans.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com The FDA Approves Rocket Pharmaceuticals' Kresladi For Pediatric Patients With Severe Leukocyte Adhesion Deficiency-I First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by…
- benzinga.com Rocket Pharmaceuticals Enters Sales Agreement With Cantor Fitzgerald & Co. For ATM Offering Up To $100M https://www.sec.gov/Archives/edgar/data/1281895/000114036126008849/ny20066752x3_424b5.htm
- benzinga.com Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3 Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
benzinga.com Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10 Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.- benzinga.com Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.04 percent. This is a 38.71 percent increase over losses…
benzinga.com B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $8 B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $10 to $8.
benzinga.com Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
benzinga.com FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by March 2026.- benzinga.com Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $11 Price Target Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price target.
benzinga.com Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com The FDA Has Accepted The Resubmission Of Rocket Pharmaceuticals' Marketing Application For Kresladi (Marnetegragene Autotemcel; Marne-cel), An Investigational Gene Therapy For Severe Leukocyte Adhesion Deficiency-I. PDUFA Date Is March 28, 2026 Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KRESLADI was well toleratedRocket is eligible for a Rare Pediatric Disease…
- benzinga.com Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $7 Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $9 to $7.
benzinga.com FDA Outlines Process To Speed Up Rare Disease Therapy Approvals FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.- benzinga.com Rocket Pharmaceuticals CFO Aaron Ondrey Resigns; Martin Wilson Appointed Interim CFO Effective September 8 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.On August 20, 2025, Aaron Ondrey resigned as…
- benzinga.com 'The European Medicines Agency Just Disclosed That Rocket Pharmaceuticals Has Withdrawn Its Application For Marketing Authorization Of Fanskya; The EMA Concluded That The Benefit Of Mozafancogene Autotemcel Did Not Outweigh Its Risks' - EMA https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-mozafancogene-autotemcel_en.pdf
benzinga.com Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - benzinga.com B of A Securities Upgrades Rocket Pharmaceuticals to Buy, Raises Price Target to $10 B of A Securities analyst Jason Zemansky upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Buy and raises the price target from $4 to $10.
- benzinga.com Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $11 Price Target Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price target.
benzinga.com TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday 
benzinga.com FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and updated treatment protocol.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com The FDA Lifts Clinical Hold On Rocket Pharmaceuticals' Pivotal Phase 2 Trial Of RP-A501 For Danon Disease In its correspondence, the FDA confirmed that Rocket satisfactorily addressed issues outlined in the clinical hold. The FDA authorized the pivotal study to resume first with a recalibrated dose of…
benzinga.com What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.